Skip to main content
Katie Kalvaitis on Muck Rack

Katie Kalvaitis

Verified
Philadelphia
As seen in: Endocrine Today, Healio, Healio Cardiac/Vascular Intervention, Healio Women’s Health & OB/GYN, Healio Cardiology, Healio Dermatology, HemOnc Today, Nephrology News & Issues, Healio Pulmonology, Citeline
Medical editor & reporter. All tweets my own. @cardiologytoday @gohealio @endocrinetoday @healiowomen
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katie

Contact Katie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

American Diabetes Association Scientific Sessions Original

|
By Katie Kalvaitis Verified
| Endocrine Today Verified
Key takeaways: Elecoglipron is an oral small-molecule, nonpeptide GLP-1 receptor agonist being investigated for daily use. Researchers reported clinically meaningful improvements in HbA1c and body weight. NEW ORLEANS — A novel oral small-molecule GLP-1 receptor agonist demonstrated reductions in HbA1c and body weight among individuals with type 2 diabetes and obesity. Researchers presented results from the phase 2 SOLSTICE and VISTA studies at the American Diabetes Association Scientific Sessions.
Open in Who Shared View Duplicates (2) Issue with article?

American Diabetes Association Scientific Sessions

|
By Katie Kalvaitis Verified, Erik Swain Verified, Vanita R. Aroda
| Citeline Verified
Elecoglipron, an oral daily GLP-1, confers glucose, weight reduction in phase 2 studies Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared Issue with article?

American Diabetes Association Scientific Sessions Original

|
By Katie Kalvaitis Verified, Michael Monostra Verified
| Endocrine Today Verified
Key takeaways: Orforglipron 3 mg, 12 mg and 36 mg reduced HbA1c more than dapagliflozin 10 mg at 40 weeks in the ACHIEVE-2 trial. Orforglipron was tied to a larger HbA1c decrease than oral semaglutide in ACHIEVE-3. NEW ORLEANS — Once-daily orforglipron induced greater reductions in HbA1c than dapagliflozin and oral semaglutide for adults with type 2 diabetes, according to findings from the ACHIEVE-2 and ACHIEVE-3 trials.
Open in Who Shared View Duplicates (2) Issue with article?
See all 465 articles